SCI / RSC 22nd Medicinal Chemistry Symposium

Synopsis

The organisers invite you to the 22nd SCI-RSC Medicinal Chemistry symposium, Europe’s premier biennial Medicinal Chemistry event, focusing on first disclosures and new strategies in Medicinal Chemistry.

---

Attendees

SCI and RSC members will be able to register at discounted rates which are detailed on the fees section further down the page.

• SCI members should login with their account details
• RSC members should enter the Event discount code EJRFChem221  and select “Guest Member” under the section Member type. Delegates will be contacted for their RSC membership number after successful registration.
• RSC student members should enter the Event discount code EJRFChem221S and select “Guest Member” under the section Member type. Delegates will be contacted for their RSC membership number after successful registration.
• Students who are not a member of SCI/RSC should email conferences@soci.org from their institution email address to request the relevant voucher code to book for this event

---

Call for posters

A number of places will be reserved for poster presenters and contributions are invited from the whole field of medicinal chemistry. To enable presenters to receive approval from their institutions, there will be early and final submission dates of 28 April and 7 July 2023 respectively. Download an abstract template here and submit to conferences@soci.org.

---

Exhibition and Sponsorship

Churchill College is an ideal venue for exhibitors. All refreshments, the exhibition and posters will be situated in a single area, ensuring excellent access to delegates throughout the meeting.

The exhibition will run alongside the conference during refreshment breaks and poster sessions. Those who wish to exhibit are encouraged to book early to avoid disappointment. Exhibition stands will be available to book via the registration page when registration opens, and the rate will include two stand staff and daytime refreshments.  

For further details, please contact conferences@soci.org

---

Confirmed Talks

The discovery of sebetralstat, an oral, small molecule oral plasma kallikrein inhibitor to treat attacks of hereditary angioedema

Rebecca Davie, KalVista

Discovery of reversible highly potent and selective MAGL inhibitors 

Uwe Grether, Roche

Discovery and first-time disclosure of NT-0796, a clinical phase NLRP3 inflammasome inhibitor for inflammation

David Harrison, NodThera

LMW inhibitors of IL-1β, from fragment hits to cellular PoC

Konstanze Hurth, Novartis Institutes for BioMedica

Discovery of LAS202051, a potent Acetyl-CoA Carboxylase (ACC) inhibitor for the topical treatment of acne

Jordi Bach Taña, Almirall

Discovery of a novel class of brain penetrant inhibitors of KRAS G12C

Jason Kettle, AstraZeneca

Fadaltran, a Selective Antagonist for the Peripheral AR alpha 2c Receptors: A New Option for the Treatment of Diabetic Foot Ulcers?

Carsten Schmeck, Bayer

Fragment-based drug discovery approaches to the development of protein-protein interaction inhibitors

Dr John Skidmore, The ALBORADA Drug Discovery Institute, University of Cambridge

Plasmepsin X inhibitors with in vivo antimalarial activity

Teresa de Haro Garcia, UCB

Discovery of VX-147 as a Targeted Therapy for APOL1‑mediated Kidney Disease’

Les Dakin, Vertex

Lessons Learnt building the GSK pan-BET bromodomain portfolio

Phil Humphreys, GSK

Gamma Secretase Modulator for the treatment of Alzheimer's Disease

Rosa Maria Rodriguez Sarmiento, Hoffman La Roche

SAGE-718, a compound in phase II for a variety of CNS indications. (NMDAR PAM)

Matthew Hill

Lenacapavir, a First-in-class Long-Acting HIV Capsid Inhibitor

Eda Canales, Gilead 

Structure-based Discovery of GS-9770: The Road to a Novel, Unboosted, HIV Protease Inhibitor 

Ana Z. Gonzalez, Gilead

Allosteric SHP2

Astex

Design and Discovery of MRTX0902: An Inhibitor of the SOS1:KRAS Protein-Protein Interaction

Chris Smith, Mirati

Discovery of EDI048, a GI-targeted soft-drug for the treatment of chronic pediatric cryptosporidiosis.

Joe Young, Novartis

Pre-clinical and clinical evaluation of NDI-034858

Silvana Leit, Nimbus

Malaria therapy based on plasmodium Phosphatidylinositol-4-kinase and host hemoglobin degradation pathway

Godwin Dziwornu, H3D

Positive allosteric modulators of the α7 nAChR for the treatment of cognitive disorders: Invention of MK-4334

Ian Bell, Merck US

In Silico Enabled Discovery of Potent, Selective and Brain-penetrant DLK Inhibitors for the Treatment of Neurodegenerative Diseases

Rachel Lagiakos, Schrodinger

Data-driven optimisation of azabenzimidazoles as mGluR2 modulators for CNS disorders

Dr Sarah Major, Evotec

KCNK13 blocker

Kevin Doyle, Cerevance 

AI-driven Drug Discovery Delivers Phase 1/2 Clinical A2AR Antagonist

Thorsten Nowak, Exscientia

Discovery of PF-07817883: A next generation oral protease inhibitor for the treatment of COVID-19

Matthew Sammons, Pfizer

a7 PAM

Andrew Bell, Myricx Pharma

Pre-clinical and clinical evaluation of NDI-034858

Godwin Dziwornu, H3D

Arginase inhibitors for the treatment of cancer

Scott Mlynarski, Astrazeneca

Substrate Reduction Therapy for the Treatment of Metachromatic Leukodystrophy

Suga Thurairatnam

Hall of Fame winner - Karin Briner

Malcolm Campbell Prize Winner - Charles Coombes -  Samuraciclib

---

Medchem Workshop

 Sunday 13:30 - 16:30

As part of the conference, we are pleased to offer the opportunity to participate in a Medicinal Chemistry Workshop which will take place on the Sunday afternoon.

The workshop is based on an interactive, team-based game that allows you to explore various aspects of the drug discovery process. Delegates will work together in teams with peers from other organisations and the learning experience will be facilitated by a dedicated and diverse team of experienced professional medicinal chemists from across the pharmaceutical industry. This is a great way to accelerate your learning curve in medicinal chemistry, learning from your peers and our experts and it’s a lot of fun to play!

This event will be of interest to early career scientists, typically with five years or fewer post-graduate experience in medicinal chemistry.

To register your interest, please click here. There is no additional charge associated with participation in the workshop but places are limited

---

Accommodation and Conference Dinners

Accommodation for 3 nights (Sun 10 Sept, Mon 11 Sept and Tues 12 Sept) is available to book on registration for the event, as follows:

Package 1 - Conference only, NO accommodation and NO dinners included
Package 2 - Conference + 3 nights STANDARD en-suite accommodation, including dinners
Package 3 - Conference + 3 nights SUPERIOR en-suite accommodation, including dinners

Packages 2 and 3 also include breakfast and attendance to three conference dinners as follows:

• BBQ dinner on Sunday
• Dinner on Monday
• Gala Dinner on Tuesday

If you are booking Package 1 (no accommodation or dinners included), you can choose to book onto one or more of the evening dinners as optional extras.

If you require an extra night of accommodation above the 3 included in accommodation packages, please email conferences@soci.org. This is subject to availability

---

Programme

The programme will be announced in due course. 

---

Venue and Contact

---

Fees

---

Booking Process/Deadlines

Booking terms and conditions

---

Bursaries

A limited number of student bursaries are available as a contribution to the cost of registration fees, travel and accommodation. For more information and to receive an application form, please contact conferences@soci.org.

---

---

---

Organising Committee

Nadia Ahmad, Charles River
Mark Healy, Novartis
Joanne Pinder , Vertex 
Jamie Scott, AstraZeneca
John Cumming, Roche
Gordon Saxty, NS-MC Consulting 
Chris Swain, Cambridge MedChem Consulting
Andrew Williams, Chairman of the RSC BMCS

---